Home | Advanced Search | Downloads | Login | Contact Us

Quick-Med Technologies, Inc. Receives Key Patent On Its NIMBUS™ Technology U.S. Patent Allowance Significantly Strengthens Overall Patent Portfolio

Gainesville, FL – December 8, 2005 – Quick-Med Technologies, Inc., (OTC Bulletin Board: QMDT) (“QMT”), a life sciences company focused on developing broad-based technologies within the healthcare and consumer markets, is pleased to announce a significant addition to its NIMBUS™ intellectual property (IP) portfolio.

The U.S. Patent and Trademark Office (USPTO) has given notice of allowance to QMT of patent application entitled “Intrinsically Bactericidal Absorbent Dressing and Method of Fabrication - No. 09/857,906”. Similar patents have now been allowed in China, Australia and Russia.

“This patent marks a milestone in building our NIMBUS IP portfolio,” stated Gerald M. Olderman, PhD., Vice President, Research & Development of Quick-Med Technologies, Inc. “This broadened IP is another step toward accelerating business development in the U.S., particularly in wound dressings and advanced fabrics. ” Mr. Olderman added.

NIMBUS technology employs a powerful microbicidal agent that can be permanently bonded to materials such as cotton, rayon or polyurethane to create advanced wound dressings, fabrics or other medical or consumer products. The Company has recently announced the finding that NIMBUS is highly effective against key strains of bacteria that have become resistant to antibiotics commonly used to treat infections, including MRSA (Methicillin-Resistant Staphylococcus aureus) and VRE (Vancomycin-Resistant Enterococcus) -- two of the most important antibiotic-resistant organisms that cause hospital and nursing home infections.(1)

“Timing is critical in today’s antimicrobial market, and we believe that we are well positioned with a technology able to combat some of the emerging bacteria-related health risks.” said David S. Lerner, President of Quick-Med Technologies, Inc.

QMT has made substantial progress in developing its IP portfolio surrounding NIMBUS technology. Patents have also been granted in other countries, including (i) China (Patent No. 99814229.8) issued on January 12, 2005, (ii) Australia (Patent No. 773532) issued on May 27, 2004, and (iii) Russia (Patent No. 04160) issued on February 26, 2004. These other patents share the same title as the above referenced U.S. patent. Additional information regarding the Company’s IP portfolio can be found in the Company's Form 10-KSB for the fiscal year ended June 30, 2005 filed with the Securities and Exchange Commission.

About MRSA and VRE

In 1999, MRSA accounted for more than 50 percent of all Staphylococcus aureus infections within U.S. intensive care units (ICU). This proportion increased to more than 60 percent in 2003. VRE rates have continued to increase and now account for more than 25 percent of ICU enterococci infections, according to the National Nosocomial (hospital acquired) Infections Surveillance system. Mortality rates for VRE bacteremia and sepsis (infection in the blood) have been reported to exceed 30 percent.(2)

According to The Pennsylvania Healthcare Cost Containment Council (“PHC4”) report dated July 2005, Pennsylvania hospitals had 11,668 confirmed hospital-acquired infections in 2004. Further, according to this report, the hospital admissions in which these infections occurred were associated with 1,793 deaths, and an estimated 205,000 extra hospital days and $2 billion in additional hospital charges. These numbers are out of a total of 1.5 million discharges from 173 general acute care hospitals.(3)

Based on current trends, it appears MRSA and VRE will be increasingly problematic, not only in acute care settings, but also in long-term care facilities and the community.

Source:

Quick-Med Technologies, Inc. and The University of Florida Collaborate to Develop The Next Generation of NIMBUS™ Antimicrobial Technology - September 13, 2005 Press Release
North Dakota Department of Health – May/June 2004 Epidemiology Report.
PHC4 Research Brief – Issue No. 5 July 2005: Hospital-Acquired Infections in Pennsylvania.

About NIMBUS™

NIMBUS™ employs long molecular chains of microbicidal groups that can be attached to a variety of substrates, including wound dressings, fibers, paper, apparel, and even hospital bedding and gowns.

About Quick-Med Technologies, Inc.

For additional information, visit Quick-Med Technologies' website: http://www.quickmedtech.com or email at info@quickmed-technologies.com. For Details, Contact: David S. Lerner, President at 561-750-4202. For Investor Relations, Contact: Natasha A. Sorobey at 561-208-8259

Forward Looking Statement

Certain statements in this press release constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, certainties and other factors, which may cause the actual results, performance of achievements of Quick-Med Technologies, Inc. (the “Company”) to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The approval of the patent application for the NIMBUS technology entitled “Intrinsically Bactericidal Absorbent Dressing and Method of Fabrication” by the United States Patent and Trademark Office should not be construed as an indication in any way whatsoever of having any positive impact upon our future financial performance or stock price. The Company’s future operating results are dependent upon many factors, including whether the Company will ever successfully launch its potential technologies and/or products, and the risk factors contained in its periodic and other filings, which are available for review at www.sec.gov. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events, or circumstances after the date of such statement.